60 Degrees Pharmaceuticals, INC 8-K filings

60 Degrees Pharmaceuticals, Inc. announced the results of its 2026 Annual Stockholders Meeting, with shareholders approving several critical proposals including a reverse stock split and an amendment to the equity incentive plan.

60 Degrees Pharmaceuticals announced a private placement of common stock and warrants, raising approximately $1 million to fund working capital and research and development.

60 Degrees Pharmaceuticals, Inc. has updated its investor presentation, highlighting its malaria prevention product ARAKODA and its pipeline for tick-borne diseases, including babesiosis.

60 Degrees Pharmaceuticals is preparing a statistical analysis plan for an interim review of its severe babesiosis trial, with potential for early reporting or sample size adjustments.

60 Degrees Pharmaceuticals, Inc. disclosed plans to seek a National Priority Review Voucher if its babesiosis trial results support an NDA submission by Q1 2028.

60 Degrees Pharmaceuticals, Inc. announced the appointment of Eric Francois to its Board of Directors, effective immediately.

60 Degrees Pharmaceuticals, Inc. filed an 8-K to correct an error in the reported beneficial ownership of an affiliate's common stock.

60 Degrees Pharmaceuticals filed an updated legal opinion confirming the validity of shares for its At-The-Market equity offering program.

60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion confirming the validity of shares under its existing At-The-Market equity offering program.

60 Degrees Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, averting a delisting.

60 Degrees Pharmaceuticals, Inc. received a notice from Nasdaq regarding the delisting of its common stock and warrants due to a failure to maintain the minimum bid price and a recent reverse stock split.

60 Degrees Pharmaceuticals, Inc. announced a one-for-four reverse stock split, effective January 20, 2026, primarily to regain Nasdaq minimum bid price compliance.

60 Degrees Pharmaceuticals, Inc. provided an investor presentation detailing updated clinical development timelines and its regulatory strategy for Tafenoquine, including its potential for chronic babesiosis treatment.

60 Degrees Pharmaceuticals, Inc. stockholders approved a reverse stock split, director elections, and an increase in the equity incentive plan at their 2025 Annual Meeting.

60 Degrees Pharmaceuticals outlines its strategy for increasing ARAKODA sales, focusing on chronic babesiosis and malaria prevention, alongside ongoing clinical trials and regulatory goals.

60 Degrees Pharmaceuticals establishes a new At-The-Market equity offering for up to $1.4 million, replacing a prior agreement.

60 Degrees Pharmaceuticals, Inc. has successfully closed a public offering, raising $5 million in gross proceeds with the potential for an additional $5 million from warrant exercises, to fund working capital and general corporate purposes, despite disclosing substantial doubt about its ability to continue as a going concern.

60 Degrees Pharmaceuticals has entered into an option agreement to potentially license patent rights related to large-scale purification of castanospermine, a bioactive alkaloid.

60 Degrees Pharmaceuticals has successfully completed a registered direct offering, raising $1.075 million to support working capital and general corporate purposes.

60 Degrees Pharmaceuticals has secured $1.043 million through a registered direct offering and concurrent private placement of warrants.

60 Degrees Pharmaceuticals announces IRB approval for a Phase II clinical study evaluating tafenoquine (ARAKODA) for the treatment of chronic babesiosis, with patient enrollment expected to begin in Q3 2025.

60 Degrees Pharmaceuticals has enrolled the first patient in an expanded access clinical study to evaluate tafenoquine for treating persistent babesiosis.

60 Degrees Pharmaceuticals successfully obtained shareholder approval for warrant exercises, an equity incentive plan amendment, and a reverse stock split at its 2024 Special Stockholders Meeting.

60 Degrees Pharmaceuticals has initiated a nine-month promotional pilot program for its antimalarial drug ARAKODA, focusing on increasing brand awareness and utilization through virtual sales and a co-pay program.

60 Degrees Pharmaceuticals has successfully completed a $4 million private placement to fund working capital, general operations, and research and development.

60 Degrees Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive trading days.

60 Degrees Pharmaceuticals has granted the University of Kentucky a right of reference to its malaria drug ARAKODA's new drug application to support the university's Phase IIb study of SJ733.

60 Degrees Pharmaceuticals will implement a 1-for-12 reverse stock split to meet Nasdaq's minimum bid price requirement, effective August 12, 2024.

60 Degrees Pharmaceuticals has been awarded a contract with the U.S. Army to support commercial validation of new packaging for its malaria prevention drug, ARAKODA, following a 515% year-over-year increase in Q1 2024 sales revenue.

60 Degrees Pharmaceuticals successfully held its 2024 Annual Stockholders Meeting, approving the election of directors, an increase in share availability for the equity incentive plan, a reverse stock split, and other key proposals.